The shadow of generic competition has long loomed around copyright’s iconic drug, Viagra, triggering questions about the future of related medicinal investments. While early times saw impressive gains, the patent end has opened the way for cheaper copies, possibly reducing profitability and creating a significant danger for investors pursuing sta